Clinical pharmacokinetic study suggests that glucuronidation pathways are not affected by liver diseases (revised in [14]), which is also supported by the stable protein levels of UGT1A3 and UGT1A1 in the Child–Pugh class B and C HCV livers revealed in this study. Here, UGT1A1 is linked to liver disorder.